Business Context and Reporting Period
Company: UPEXI, INC. (UPXI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2025
Business Overview: Upexi operates as a brand owner for consumer products and has pivoted its treasury strategy to focus on holding and staking Solana (SOL) digital assets. The company manages a significant cryptocurrency portfolio, primarily through Solana tokens, while continuing to develop and distribute consumer products. As of December 31, 2025, the company holds approximately 2.17 million SOL tokens.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Total Revenue | $8,052,040 | $17,291,785 |
| Digital Asset Revenue (Staking) | $5,143,513 | $11,227,130 |
| Product Revenue | $2,908,527 | $6,064,655 |
| Net Loss | $(178,924,930) | $(112,176,808) |
| Loss Per Share (Basic & Diluted) | $(2.94) | $(1.93) |
| Cash and Cash Equivalents | $1,616,765 | $1,616,765 |
| Total Digital Assets (Fair Value) | $255,702,381 | $255,702,381 |
| Total Assets | $271,144,765 | $271,144,765 |
| Total Liabilities | $222,428,036 | $222,428,036 |
| Working Capital | $93,398,029 | $93,398,029 |
Debt Profile:
- Convertible Notes: $144,115,480 (Net of deferred financing costs), due July 2027. These notes are convertible into common stock at $4.25/share or repayable in SOL tokens.
- Short-Term Treasury Debt (BitGo Facility): $62,695,723 outstanding, interest rate 11.5%.
- Cygnet Subsidiary Notes: $5,380,910 (Current portion).
- Promissory Notes: $560,000 (Current portion).
Material Changes vs. Prior Period
- Revenue Composition: Total revenue increased significantly due to the introduction of digital asset revenue ($5.1M for the quarter), offsetting a 27.4% decline in traditional product revenue ($2.9M vs. $4.0M prior year).
- Net Loss Expansion: Net loss widened dramatically to $178.9M for the quarter (vs. $1.3M loss prior year) and $112.2M for the six months (vs. $2.9M loss prior year). This is primarily driven by a $164.5M unrealized loss on digital assets for the quarter.
- Operating Expenses: General and administrative expenses surged to $5.5M for the quarter (vs. $1.5M prior year), driven by public company costs, professional fees, and stock-based compensation ($8.3M for the quarter).
- Balance Sheet Shift: Total assets more than doubled from $123.8M (June 30, 2025) to $271.1M (Dec 31, 2025), largely due to the accumulation of digital assets valued at $255.7M.
- Manufacturing Exit: The company recorded a $1.4M impairment loss related to the shutdown of certain manufacturing and distribution operations (hemp/health and wellness products).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Strategy:
- Solana Treasury: Management is exclusively focused on a Solana treasury strategy, staking approximately 95% of holdings to generate yield. They do not intend to hedge SOL exposure.
- Capital Allocation: Resources are being reallocated from traditional manufacturing to the digital asset strategy. The company expects product revenue to remain flat or decline as marketing spend is reduced.
- Liquidity: The company estimates sufficient working capital to fund operations for the next 12 months. A shelf registration statement was declared effective on January 8, 2026.
Risks and Contingencies:
- Asset Management Dispute: The company is in active arbitration with GSR Strategies LLC regarding an Asset Management Agreement. GSR alleged a default; Upexi disputes this and seeks to void the agreement. GSR has filed counterclaims for damages.
- Internal Controls: Management concluded disclosure controls and procedures were not effective due to material weaknesses, specifically inadequate segregation of duties and lack of multiple levels of supervision.
- Legal Proceedings: Pending litigation includes claims from Bloomios (fraud/breach of contract regarding Infusionz acquisition) and MVW Holdings (trade-dress lawsuit).
- Market Volatility: Significant exposure to Solana price volatility, which directly impacts reported net income through unrealized gains/losses.
Unusual Items:
- Unrealized Losses: $164.5M unrealized loss on digital assets for the quarter due to SOL price depreciation relative to cost basis.
- Stock-Based Compensation: $8.3M expense for the quarter, including $4.4M related to the termination of the asset management agreement warrants.
Investor Verification Checklist
- Digital Asset Valuation: Verify the fair value methodology for locked vs. liquid SOL tokens and the 14% discount applied to locked tokens.
- Debt Conversion Terms: Review the terms of the $144M convertible notes, specifically the conversion price ($4.25) and the option to repay in SOL tokens.
- Arbitration Outcome: Monitor the status of the arbitration with GSR Strategies LLC, as counterclaims could result in significant monetary damages.
- Internal Control Remediation: Assess the timeline and plan for remedying the material weaknesses in internal controls over financial reporting.
- Manufacturing Shutdown: Confirm the completion of the exit from hemp/health and wellness manufacturing operations and associated cost savings.
- Subsequent Events: Note the January 2026 issuance of a new $36M convertible note and the February 2026 registered direct offering of 6.3M shares.